<DOC>
	<DOCNO>NCT01506375</DOCNO>
	<brief_summary>The aim study compare safety , clinical tolerability , immunogenicity efficacy gpASIT+TM ( grass pollen peptide ) alone combine immunoregulating adjuvant , short course administration ( 5 injection 4 week ) .</brief_summary>
	<brief_title>Safety gpASIT+TM Subcutaneously Administered Hay Fever Patients With Without Immunoregulating Adjuvant</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Subject give write informed consent Age 18 50 year The subject good physical mental health accord his/her medical history , vital sign , clinical status Male nonpregnant , nonlactating female Females unable bear child must documentation CRF ( i.e . tubule ligation , hysterectomy , postmenopausal ( define minimum one year since last menstrual period ) ) Allergy diagnosis : A medical history moderate severe seasonal allergic rhinoconjunctivitis ( SAR ) grass pollen season least two previous year A positive skin prick test ( wheal diameter ≥ 3 mm ) grasspollen mixture Specific IgE grass pollen ( IgE &gt; 0.7 kU/l ) [ use recombinant mixture rPhl p1 rPhl p5b Phleum pratense ( g213 ) ] Subjects never treat immunotherapy subject immunotherapy end December 31 , 2009 well moderate severe symptom two previous year ( 2010 2011 ) Subjects current immunotherapy subject underwent previous immunotherapy within last 2 year Participation another clinical trial and/or treatment experimental drug within last 3 month A history hypersensitivity excipients investigational product Subjects perennial asthma ( regular intake inhale corticosteroid outside pollen season : consumption daily base patient take reliever twice week ) Subjects severe seasonal asthma require long act beta agonist AND inhale steroid treatment Subjects VC &lt; 80 % FEV1 &lt; 70 % predict value screen visit Subjects symptomatic perennial inhalant allergen need antihistamine drug systemic corticoid relieve allergic symptom treatment period Subjects document evidence chronic sinusitis ( determined Investigator ) Subjects rhinitis medicamentosa , nonspecific rhinitis ( food dye , preservative agent… ) Subjects history renal disease chronic hepatic disease Subject malignant disease , autoimmune disease Any chronic disease , may impair subject 's ability participate trial Subjects require betablockers medication Chronic use concomitant medication would affect assessment effectiveness trial medication ( e.g . tricyclic antidepressant ) Regular consumption corticoid ( oral , topic nasal ) antihistaminic drug within 4 week precede trial ( screen visit ) Any consumption corticoid ( oral , topic nasal ) antihistaminic drug within 1 week precede trial ( screen visit ) Subject febrile illness ( &gt; 37.5°C , oral ) A know positive serology HIV1/2 , HBV HCV Subjects immunocompromised medication illness , receive vaccine , corticoid immunosuppressive medication within 1 month trial entry Receipt blood blood derivative past 6 month precede trial entry Female subject pregnant , lactating , childbearing potential protected pregnancy sufficiently reliable method Any condition could incompatible protocol understand compliance Subjects forfeit freedom administrative legal award guardianship Unreliable subject include noncompliant subject , subject know alcoholism drug abuse history serious psychiatric disorder well subject unwilling give inform consent abide requirement protocol Subjects without mean contact Investigator rapidly case emergency , able contact rapidly Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>seasonal allergic rhinoconjunctivitis</keyword>
	<keyword>grass pollen</keyword>
	<keyword>allergen specific immunotherapy</keyword>
</DOC>